2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras
  5. Ras Isoform

Ras

Ras proteins are small GTPases that function as molecular switches, cycling between inactive GDP-bound and active GTP-bound states to regulate intracellular signaling networks controlling cell proliferation, differentiation, migration, survival, and apoptosis[1][2]. Mechanistically, activated Ras transduces signals from cell-surface receptors to major downstream pathways, including the RAF-MEK-ERK cascade, thereby coordinating growth-related transcriptional programs and cellular responses[1][2]. The human RAS family comprises the highly homologous isoforms KRAS, NRAS, and HRAS, which share common effectors yet display distinct signaling outputs, partly due to sequence divergence within regions involved in allosteric communication and membrane interactions[3][4]. Compared with related isoforms, KRAS exhibits unique membrane-targeting characteristics associated with its hypervariable region and is the predominant RAS isoform mutated in human malignancies, whereas NRAS and HRAS show different mutation frequencies and biological distributions across cancer types[4][5][6]. RAS genes are among the most frequently mutated oncogenes in human cancer, and gain-of-function mutations commonly affecting codons 12, 13, and 61 promote persistent Ras activation that drives tumorigenesis in diverse experimental and clinical settings[5][7]. For experimental applications, isoform-selective signaling mechanisms and Ras conformational regulation provide important frameworks for the development and evaluation of Ras-targeted inhibitors and mechanistic cancer models[3][8].

Ras Related Products (421):

Cat. No. Product Name Effect Purity
  • HY-153724
    BI-2865
    		99.16%
    BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM).
  • HY-12755
    ML141
    		Inhibitor 99.96%
    ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines.
  • HY-15723A
    NSC 23766 trihydrochloride
    		Inhibitor 99.41%
    NSC 23766 trihydrochloride is an inhibitor of Rac1 activation.
  • HY-13452
    CID-1067700
    		Inhibitor 99.71%
    CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.
  • HY-12646
    Rhosin hydrochloride
    		Inhibitor 99.94%
    Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor. Rhosin hydrochloride specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin hydrochloride induces cell apoptosis. Rhosin hydrochloride promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability.
  • HY-107753
    XRP44X
    		Inhibitor 98.09%
    XRP44X inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules.
  • HY-N9330
    Broussoflavonol F
    		Inhibitor 98.11%
    Broussoflavonol F is a potent dual inhibitor of the HER2-RAS-MEK-ERK signaling pathway and mushroom tyrosinase with an IC50 value of 82.3 μM. Broussoflavonol F downregulates the expression of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk proteins. Broussoflavonol F induces cell cycle arrest and apoptosis, and exhibits cytotoxicity in colon cancer cells. Broussoflavonol F inhibits endothelial proliferation, migration and tube formation, suppresses subintestinal vascular development, and reduces the mRNA levels of angiogenesis-associated genes.Broussoflavonol F can be used for colon cancer research.
  • HY-123673
    MCP110
    		Inhibitor 99.82%
    MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.
  • HY-15723
    NSC 23766
    		Inhibitor 99.86%
    NSC 23766 is a cell-permeable, reversible and specific inhibitor of Rac GTPase, used for cancer treatment.
  • HY-15136
    Lonafarnib
    		Inhibitor 99.85%
    Lonafarnib (Sch66336) is a potent and orally active, and CNS-penetrant farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
  • HY-16659
    EHT 1864
    		Inhibitor 99.85%
    EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The Kd values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG.
  • HY-12874
    CASIN
    		Inhibitor 99.89%
    CASIN is a selective GTPase Cdc42 inhibitor with an IC50 of 2 uM. CASIN can be used for the research of cancer.
  • HY-112473
    Grassofermata
    		Inhibitor 99.10%
    Grassofermata is a dual Arf1/Arf6 activation inhibitor. ADP ribosylation factors (Arfs) are members of the Arf family of GTP-binding proteins of the Ras superfamily.
  • HY-157228
    ACBI3
    		Degrader 99.47%
    ACBI3 (compound 7), a chemical probe, is a PROTAC targeting KRAS. ACBI3 achieves in vivo degradation of oncogenic KRAS, resulting in durable pathway modulation and tumor regressions in KRAS mutant xenograft mouse models.
  • HY-19800
    ML-098
    		Activator 99.91%
    ML-098 (CID-7345532) is an activator of the GTP-binding protein Rab7 with an EC50 of 77.6 nM.
  • HY-12810
    EHop-016
    		Inhibitor 99.38%
    EHop-016 is a potent and selective Rac GTPase Rac1 and Rac3 inhibitor. EHop-016 inhibits Rac1 activity with an IC50 of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration.
  • HY-125792
    Nexinhib20
    		Inhibitor 99.86%
    Nexinhib20 is an inhibitor that targets the interactions of Rab27a-JFC1 (IC50: 2.6 μM) and Rac-1-GTP. Nexinhib20 can inhibit neutrophil exocytosis, adhesion, and β2 integrin activation, and has anti-inflammatory activity. Nexinhib20 can be used in the research of diseases such as systemic inflammation and myocardial ischemia-reperfusion injury.
  • HY-13991
    CCG-1423
    		Inhibitor 99.88%
    CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes.
  • HY-126370A
    Geranylgeranyl pyrophosphate triammonium
    		Activator
    Geranylgeranyl pyrophosphate triammonium is a type of isoprenoid metabolic intermediate, mainly synthesized through the mevalonate pathway. Geranylgeranyl pyrophosphate triammonium is a key precursor in various biological synthesis processes, especially as a necessary substrate for post-translational modification of proteins - geranylgeranyl phosphorylation. Geranylgeranyl pyrophosphate triammonium regulates various cellular processes and disease progression through protein geranylgeranyl phosphorylation, such as activating the YAP signaling pathway, promoting cell proliferation and inhibiting apoptosis; promoting IL-2 production and STAT5 phosphorylation; and influencing metabolic homeostasis and cancer, etc.
  • HY-12646A
    Rhosin
    		Inhibitor 98.74%
    Rhosin is a potent, specific RhoA subfamily Rho GTPases inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis. Rhosin promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability.
Cat. No. Product Name / Synonyms Application Reactivity